<i>Lactobacillus bulgaricus </i>inhibits colitis-associated cancer via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium sulfate model
Denise Sayuri Calheiros da Silveira, Luciana Chain Veronez, Luís Carlos Lopes‐Júnior, Elen Anatriello, Mariângela Ottoboni Brunaldi, Gabriela Pereira-da-Silva
Abstract
BACKGROUND: Colitis-associated cancer (CAC) accounts for 2%-3% of colorectal cancer (CRC) cases preceded by inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. Intestinal microbiota has been reported to play a central role in the pathogenesis of IBD and CAC. Recently, numerous prebiotics and probiotics have being investigated as antitumor agents due to their capacity to modulate inflammatory responses. Previous studies have indicated that lactic acid bacteria could be successfully used in managing sporadic CRC, however little is known about their role in CAC. AIM: ) during the development of an experimental model of colitis associated colon cancer (CAC). METHODS: < 0.05. Graphs were generated and statistical analysis performed using the software GraphPad Prism 6.0. RESULTS: treatment inhibited of total tumor volume and mean size of tumors. In addition, the probiotic also attenuated the clinical signs of intestinal inflammation inducing a decrease in intestinal and tumor levels of IL-6, TNF-α, IL-17, IL-23 and IL-1β. CONCLUSION: regulates the inflammatory response and preventing CAC.